article thumbnail

C4XD and AstraZeneca enter $402m deal to develop respiratory disease therapy

Pharmaceutical Technology

According to the deal, C4XD is entitled to get up to $16m in pre-clinical milestone payments before the commencement of the first clinical trial. . on meeting clinical development and commercial milestones in the future, in addition to tiered royalty payments, upon the marketing of the product.

article thumbnail

Gene Therapy and Pharmacokinetics

Camargo

Gene therapy, which was in its infancy around 30 years ago, is now becoming a more prominent treatment method in many therapeutic areas, from personalized therapy to mass vaccinations against COVID-19. PK Planning for Gene Therapy Development Programs. Gene Expression Considerations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Another Astellas gene therapy hits a safety hurdle

pharmaphorum

The delivery vector – an AAV8 capsid – is designed to allow gene expression directly in target tissues like skeletal muscle. AT845 uses the same adeno-associated virus (AAV) vector platform as AT132, but so far there have been no reports of liver toxicity with the Pompe disease candidate.

article thumbnail

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

XTalks

We are exceptionally pleased to commence dosing of our oral DNA vaccine for COVID-19 as we continue scale-up and manufacturing activities for future clinical development,” Symvivo’s chief medical officer Eric Sievers said in a press release from the company. Related: Red Meat Allergy Test Gets FDA Clearance. “We

article thumbnail

Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock – Jan 20, 2021

The Pharma Data

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression.

article thumbnail

Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

The Pharma Data

1 and COX-2 gene expression. Members of the senior management team have a combined experience in the biopharmaceutical industry, spanning clinical development, regulatory, financial and business management in both the USA and China.

article thumbnail

Advances in Genetic Medicine May Be Outpacing Some Clinicians’ Understanding, But Pharmaceutical Marketers Can Do Much to Address the Problem

Pharma Marketing Network

While this narrative will undoubtedly evolve throughout the clinical development process, the first draft should be developed as early as the IND-enabling stage. This will create an early shared understanding that will provide a framework for consistent communications throughout clinical development and post launch.